¿¬°£Á¤º¸ ¼­ºñ½º
»óǰÄÚµå
302689

½Å¾à R&D ÆÄÀÌÇÁ¶óÀÎ µ¥ÀÌÅͺ£À̽º : ¿¬°£ ±¸µ¶

R&D Drug Pipeline Database: 1-Year Subscription

¹ßÇàÁ¤º¸: | ¸®¼­Ä¡»ç: La Merie Publishing | ÆäÀÌÁö Á¤º¸: ¿µ¹®

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

º» ¿¬°£Á¤º¸ ¼­ºñ½º¿¡¼­´Â 17,000°Ç ÀÌ»óÀÇ ½Å¾à °³¹ß ÆÄÀÌÇÁ¶óÀÎ ÇÁ·ÎÁ§Æ® °ü·Ã °¢Á¾ µ¥ÀÌÅÍ¿¡ ´ëÇÑ ¿Â¶óÀÎ ¾×¼¼½º ±ÇÇÑÀ» Á¦°øÇϸç, °¢ ÇÁ·ÎÁ§Æ®ÀÇ Ç¥Àû¡¤È­ÇÕ¹° Ŭ·¡½º¡¤Á¦Ç° Ä«Å×°í¸®¡¤°³¹ß ±â¾÷¡¤Áö¿ª¡¤Ä¡·á ºÐ¾ß¡¤ÀûÀÀÁõ¡¤°³¹ß ´Ü°è µîÀÇ µ¥ÀÌÅ͸¦ ÀüÇØµå¸³´Ï´Ù.

1. º» µ¥ÀÌÅͺ£À̽ºÀÇ ÀÌÁ¡

  • Á÷°¨Àû ÀÌ¿ë °¡´É
  • 24½Ã°£ ¿Â¶óÀÎ ¾×¼¼½º °¡´É
  • ±¸Á¶ °Ë»ö¿¡ ´ëÀÀ
  • Ç¥Àû, Á¦Ç° Ä«Å×°í¸®, R&D ¼Óµµ¿¡ ÃÊÁ¡
  • °æÀï ºÐ¼®¿¡ ÃÖÀû(±â¾÷, Ç¥Àû, Á¦Ç° Ä«Å×°í¸®)
  • ³ôÀº ºñ¿ëÈ¿À²°ú ½Å¼ÓÇÑ º¥Ä¡¸¶Å· ¼Ö·ç¼Ç
  • ¶óÀ̼±½Ì Èĺ¸ ƯÁ¤ÀÌ °¡´É

2. °ÔÀç Ç׸ñ

  • ÀǾàǰ ÄÚµå
  • Ç¥Àû/ÀÛ¿ë±âÀü
  • È­ÇÕ¹° Ŭ·¡½º
  • Á¦Ç° Ä«Å×°í¸®
  • ±â¾÷
  • ±Ç¿ª(Territory)
  • Ä¡·á ºÐ¾ß
  • ÀûÀÀÁõ
  • R&D ´Ü°è

3. Á¦Ç° Ä«Å×°í¸®

  • Ç×ü
  • ¼¼Æ÷
  • DNA
  • ÆéƼµå
  • ´Ü¹éÁú
  • RNA
  • ¼ÒºÐÀÚ
  • ¹é½Å

4. Ä¡·á ºÐ¾ß

  • ½ÉÀåÇ÷°ü, Ç÷¾×, ±Þ¼ºÈ¯ÀÚ Ä¡·á
  • ÇǺΰú
  • ¼ÒÈ­±â°ú
  • ºñ´¢»ý½Ä±â, ºÎÀΰú, ½ÅÀå
  • °¨¿°Áõ, µ¶¼Ò
  • ½ÅÁø´ë»ç, ³»ºÐºñ
  • ½Å°æ ¹× ½Å°æ°ú
  • ¾Ï
  • ¾È°ú ¹× À̺ñÀÎÈİú
  • Á¤Çü¿Ü°ú, Ä¡°ú, ¸¶Ãë, ¿Ü°ú
  • Æó, È£Èí±â
  • ·ù¸ÓƼÁò, ÀÚ±â¸é¿ª

5. Ç¥Àû : »çÀü ¼³Á¤ ½ºÅ©·Ñ ´Ù¿î ¸Þ´º ¿¹

  • ADC(Antibody-Drug Conjugates)
  • Ç×ü ¹× ´Ü¹éÁú ¸ÅÃâ
  • ¼¼Æ÷³» Ç¥Àû(MAGE-A, NY-ESO-1, PRAME µî)
  • Immuno-oncology Ç¥Àû(PD-1, PD-L1, CTLA-4, LAG-3, TIM-3, 4-1 BB, CD73 µî)
  • CAR & TCR Engineered T-Cells and NK Cells
  • Adalimumab (Humira) ¹ÙÀÌ¿À½Ã¹Ð·¯
  • Her2 Ç×ü
  • ÀÌÁ߯¯À̼ºÇ×ü
  • Á¾¾ç ¿ëÇØ¼º ¹ÙÀÌ·¯½º(¾Æµ¥³ë¹ÙÀÌ·¯½º, Á¾µÎÁõ, HSV µî)
  • ¿¡º¼¶ó¹ÙÀÌ·¯½º ¹é½Å ¹× Ä¡·áÁ¦
  • ÀÀ°íÀÎÀÚ
  • º¸Åø¸®´® ½Å°æµ¶¼Ò
  • PTH-R ÀÛ¿ëÁ¦
  • ½ÉÇ÷°ü°è ÆéŸÀ̵å

6. ±â¼ú : »çÀü ¼³Á¤ ½ºÅ©·Ñ ´Ù¿î ¸Þ´º ¿¹

  • Transgenic XenoMouse Antibodies
  • T-Cell Redirecting Bispecific Antibodies
  • Agonistic Antibodies
  • TCR-like Antibodies & Fusion Proteins
  • ADC - Pyrrolobenzodiazepine(PBD)
  • Fc-Fusion Proteins
  • Oligo- and Polyclonal Antibodies
LSH 18.07.03

Subscription to La Merie Publishing's proprietary ‘R&D Drug Pieline Database’ provides 24/7 online access to information about more than 25,500 project entries (files) for therapeutic drugs on the market and on investigational drug candidates in research & development. Pre-established and free search functions allow to identify molecules according to their

  • Product category (NCE, antibodies, proteins, DNA, RNA, cells, vaccines, peptides)
  • Technology (e.g.engineered T-cells, antibody-drug conjugate, bispecific antibody)
  • Target (e.g. Her2, BCMA, PD-1, RORgamma)
  • Pipelines (selected by target, therapeutic area, company, technology)
  • Sales (for marketed antibodies, peptides and proteins)
  • R&D Phase (clinical phases, market, preclinical)
  • Territory (countrywise)
  • Therapeutic Area (e.g. infectious, oncology, gastrointestinal)
  • Drug Code/Name (for individual molecules)

Each project is specified for its Target, Therapeutic Area and R&D Phase. Use of the R&D Drug Pipeline Database is intuitive. Data sets of interest can be printed and exported as reports in Excel or Word format. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed. Sales figures of major therapeutic antibodies, proteins and peptides on the market are provided.

An advanced search function allows to combine search parameters. A scroll down menu for predefined targets and technologies conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase or company name.

Special Focus of the Database:

  • Immuno-Oncology
  • Biosimilars
  • Antibodies
  • mRNA
  • Engineered Cells
  • Oncolytic viruses
  • Therapeutic Proteins
  • Peptides
  • Vaccines

Prerequisite: Internet access.

Purchase of the subscription provides a 1-year online access to the data of the R&D Drug Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase.

Benefits from the R&D Drug Pipeline Database:

  • Intuitive use
  • 24/7 online access
  • Designed for structured searches
  • Focused on targets, product categories and R&D phases
  • Ideal for competitor analysis (companies, targets, product categories)
  • Cost-effective and rapid solution for benchmarking
  • Identification of licensing candidates

Project listing in a tabular format:

  • Drug Codes
  • Target / Mechanism of Action
  • Class of Compound
  • Product Category
  • Company
  • Territory
  • Therapeutic Area
  • Indication
  • R&D Phase

Product Categories:

  • Antibody
  • Cell
  • DNA
  • Peptide
  • Protein
  • RNA
  • Small Molecule
  • Vaccine

Therapeutic Areas:

  • Cardiovascular, blood & acute care
  • Dermatology
  • Gastrointestinal
  • Genitourinary, gynecology & renal
  • Infectious & toxicology
  • Metabolism & endocrine
  • Neurology & psychiatry
  • Oncology
  • Ophthalmolgoy & otorhinolaryngology
  • Orthopedics, dental, anesthesia & surgery
  • Pulmonary & respiratory
  • Rheumatoid & autoimmune

Examples of Predefined Targets of the Scroll Down Menu:

  • Antibody-Drug Conjugates (ADC)
  • Sales of Antibodies & Proteins 2017
  • Intracellular targets (MAGE-A, NY-ESO-1, PRAME etc)
  • Immuno-oncology targets (PD-1, PD-L1, CTLA-4, LAG-3,TIM-3, 4-1BB, CD73 etc)
  • CAR & TCR Engineered T-Cells and NK Cells
  • Adalimumab (Humira) Biosimilars
  • Her2 Antibodies
  • Bispecific Antibodies
  • Oncolytic Viruses (adenovirus, vaccinia, HSV etc)
  • Ebola Virus Vaccines & Therapeutics
  • Coagulation Factors
  • Botulinum Neurotoxins
  • PTH-R Agonists
  • Cardiometabolic Peptides

Examples of Predefined Technologies of the Scroll Down Menu:

  • Transgenic XenoMouse Antibodies
  • T-Cell Redirecting Bispecific Antibodies
  • Agonistic Antibodies
  • TCR-like Antibodies & Fusion Proteins
  • ADC - Pyrrolobenzodiazepine (PBD)
  • Fc-Fusion Proteins
  • Oligo- and Polyclonal Antibodies

Sample Screenshots of R&D Drug Pipeline Database
as of November 12, 2014.

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦